Targeting ALK Receptors in Non-Small Cell Lung Cancer: What Is the Road Ahead?

Very recently, alectinib has been demonstrated to improve efficacy outcomes compared with chemotherapy also in resected stage IB-IIIA anaplastic lymphoma kinase (ALK)-rearranged NSCLC, extending the clinical benefit offered by ALK inhibitors also to the adjuvant setting.